Janet Wiegand

Janet Wiegand

Scientific Laboratory Manager

Department: Pharmacodynamics
Business Phone: (352) 273-7735
Business Email: jwiegand@ufl.edu

Publications

2020
DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
Journal of hematology & oncology. 13(1) [DOI] 10.1186/s13045-020-00928-9. [PMID] 32677976.
2020
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
Nature communications. 11(1) [DOI] 10.1038/s41467-020-15838-0. [PMID] 32332723.
2019
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Nature medicine. 25(12):1938-1947 [DOI] 10.1038/s41591-019-0668-z. [PMID] 31792461.
2015
Metabolically programmed iron chelators.
Bioorganic & medicinal chemistry. 23(17):5954-71 [DOI] 10.1016/j.bmc.2015.06.059. [PMID] 26231739.
2014
Desferrithiocin: a search for clinically effective iron chelators.
Journal of medicinal chemistry. 57(22):9259-91 [DOI] 10.1021/jm500828f. [PMID] 25207964.
2012
Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Journal of medicinal chemistry. 55(16):7090-103 [DOI] 10.1021/jm300509y. [PMID] 22889170.
2011
Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 24(2):239-58 [DOI] 10.1007/s10534-010-9389-y. [PMID] 21103911.
2010
The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.
Journal of medicinal chemistry. 53(7):2843-53 [DOI] 10.1021/jm9018146. [PMID] 20232803.
2009
Desferrithiocin analogue uranium decorporation agents.
International journal of radiation biology. 85(4):348-61 [DOI] 10.1080/09553000902781089. [PMID] 19399680.
2009
Vibriobactin antibodies: a vaccine strategy.
Journal of medicinal chemistry. 52(12):3801-13 [DOI] 10.1021/jm900119q. [PMID] 19492834.
2008
Desferrithiocin analogues and nephrotoxicity.
Journal of medicinal chemistry. 51(19):5993-6004 [DOI] 10.1021/jm8003398. [PMID] 18788724.
2008
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
Journal of medicinal chemistry. 51(13):3913-23 [DOI] 10.1021/jm800154m. [PMID] 18533709.
2008
Impact of laughter on air trapping in severe chronic obstructive lung disease.
International journal of chronic obstructive pulmonary disease. 3(1):185-92 [PMID] 18488442.
View on: PubMed
2007
Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.
Journal of medicinal chemistry. 50(14):3302-13 [PMID] 17564424.
View on: PubMed
2006
The design, synthesis, and evaluation of organ-specific iron chelators.
Journal of medicinal chemistry. 49(24):7032-43 [PMID] 17125256.
View on: PubMed
2006
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
Journal of medicinal chemistry. 49(9):2772-83 [PMID] 16640338.
View on: PubMed
2005
Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.
Journal of medicinal chemistry. 48(3):821-31 [PMID] 15689166.
View on: PubMed
2005
Polyamine-vectored iron chelators: the role of charge.
Journal of medicinal chemistry. 48(12):4120-37 [PMID] 15943485.
View on: PubMed
2004
Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
Comparative medicine. 54(6):664-72 [PMID] 15679265.
View on: PubMed
2003
Desferrithiocin analogue based hexacoordinate iron(III) chelators.
Journal of medicinal chemistry. 46(1):16-24 [PMID] 12502356.
View on: PubMed
2003
Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.
Chirality. 15(7):593-9 [PMID] 12840823.
View on: PubMed
2003
Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
Journal of medicinal chemistry. 46(8):1470-7 [PMID] 12672247.
View on: PubMed
2003
Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model.
Digestive diseases and sciences. 48(2):399-407 [PMID] 12643622.
View on: PubMed
2002
HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Blood. 99(8):3019-26 [PMID] 11929795.
View on: PubMed
2002
Structure-activity relationships among desazadesferrithiocin analogues.
Advances in experimental medicine and biology. 509:167-84 [PMID] 12572994.
View on: PubMed
2001
Control of irritable bowel syndrome with polyamine analogs: a structure-activity study.
Digestive diseases and sciences. 46(12):2615-23 [PMID] 11768250.
View on: PubMed
2001
Significance of asymmetric sites in choosing siderophores as deferration agents.
Journal of medicinal chemistry. 44(15):2469-78 [PMID] 11448229.
View on: PubMed
2001
Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.
Journal of medicinal chemistry. 44(15):2451-9 [PMID] 11448227.
View on: PubMed
2001
Polyamine analogue antidiarrheals: a structure-activity study.
Journal of medicinal chemistry. 44(2):232-44 [PMID] 11170633.
View on: PubMed
2000
Metabolism and pharmacokinetics of N1,N11-diethylnorspermine in a Cebus apella primate model.
Cancer research. 60(16):4433-9 [PMID] 10969789.
View on: PubMed
1999
Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
Journal of medicinal chemistry. 42(1):95-108 [PMID] 9888836.
View on: PubMed
1999
Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.
Journal of medicinal chemistry. 42(13):2432-40 [PMID] 10395484.
View on: PubMed
1999
Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.
Journal of medicinal chemistry. 42(15):2881-6 [PMID] 10425097.
View on: PubMed
1999
HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Blood. 93(1):370-5 [PMID] 9864183.
View on: PubMed
1999
Pharmacokinetics of orally administered desferrithiocin analogs in cebus apella primates.
Drug metabolism and disposition: the biological fate of chemicals. 27(12):1496-8 [PMID] 10570032.
View on: PubMed
1998
HBED: A potential alternative to deferoxamine for iron-chelating therapy.
Blood. 91(4):1446-52 [PMID] 9454776.
View on: PubMed
1998
The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
Annals of the New York Academy of Sciences. 850:202-16 [PMID] 9668541.
View on: PubMed
1996
Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators.
Journal of medicinal chemistry. 39(8):1575-81 [PMID] 8648596.
View on: PubMed
1996
Metabolism and pharmacokinetics of N1,N14-diethylhomospermine.
Drug metabolism and disposition: the biological fate of chemicals. 24(3):334-43 [PMID] 8820425.
View on: PubMed
1995
Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
Drug metabolism and disposition: the biological fate of chemicals. 23(10):1117-25 [PMID] 8654201.
View on: PubMed
1994
An investigation of desferrithiocin metabolism.
Journal of medicinal chemistry. 37(18):2889-95 [PMID] 8071936.
View on: PubMed
1994
The desferrithiocin pharmacophore.
Journal of medicinal chemistry. 37(10):1411-7 [PMID] 8182699.
View on: PubMed
1993
A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Blood. 81(8):2166-73 [PMID] 8471775.
View on: PubMed
1993
A comparison of the iron-clearing properties of parabactin and desferrioxamine.
Blood. 82(8):2552-7 [PMID] 8400302.
View on: PubMed
1992
A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Blood. 79(7):1882-90 [PMID] 1558978.
View on: PubMed
1992
Structural alterations in desferrioxamine compatible with iron clearance in animals.
Journal of medicinal chemistry. 35(25):4739-44 [PMID] 1469701.
View on: PubMed
1992
Synovial and serum levels of triamcinolone following intra-articular administration of triamcinolone acetonide in the horse.
Journal of veterinary pharmacology and therapeutics. 15(3):240-6 [PMID] 1433486.
View on: PubMed
1991
Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
Journal of medicinal chemistry. 34(7):2072-8 [PMID] 2066978.
View on: PubMed
1991
Synthesis and biological evaluation of hydroxamate-based iron chelators.
Journal of medicinal chemistry. 34(11):3182-7 [PMID] 1956036.
View on: PubMed
1990
A comparative evaluation of iron clearance models.
Annals of the New York Academy of Sciences. 612:378-93 [PMID] 2127168.
View on: PubMed

Contact Details

Phones:
Business:
(352) 273-7735
Emails:
Business:
jwiegand@ufl.edu